ArticleBMC medical genomics2026
Identification and validation of PANoptosis-related genes in ankylosing spondylitis.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ankylosing spondylitis (AS) is a common immune inflammatory disease. PANoptosis, as a novel programmed cell death pathway, its mechanism of action in ankylosing spondylitis remains unclear. Therefore, this study aims to clarify the role of a novel programmed cell death pattern - PANoptosis - in the pathogenesis of ankylosing spondylitis (AS), and to screen and verify key genes (APRGS), providing new ideas for the diagnosis and treatment of AS. Based on multiple gene expression datasets (GSE25101, GSE73754, GSE11886, GSE134290) of AS patients and known gene libraries related to panoptosis, by integrating differential expression genes analysis (DEGs), weighted gene co-expression network analysis (WGCNA), protein-protein interaction network (PPI), and three machine learning algorithms (RF, LASSO-logistic regression, SVM), six core APRGs were identified: AIM2, TNF, IFNG, CASP8, ADAR, ALKBH5. These genes are significantly enriched in signaling pathways such as NOD-like receptors, TNF and p53, and exhibit excellent diagnostic efficacy for as (ROC analysis). Immune infiltration analysis revealed that as patients had characteristics such as an increase in activated NK cells and CD4+ t cells. In vivo validation was carried out by establishing a rat model of as induced by complete freesier adjuvant (CFA). HE staining showed that obvious inflammatory infiltration and abnormal ossification occurred in the sacroiliac joint of the model rats, and the levels of serum pro-inflammatory factors (TNF-α, IL-6) increased, and anti-inflammatory factors (IL-10, IL-4) significantly decreased. Molecular testing confirmed that the expression of RIPK1 protein was upregulated. The mRNA and protein expressions of AIM2, TNF, IFNG, CASP8 and ALKBH5 in core APRGs were significantly increased, while the expression of ADAR was decreased. Our research has clarified that PANoptosis drives chronic inflammation and bone destruction in as through the synergistic action of six key genes: AIM2, TNF, IFNG, CASP8, ADAR, and ALKBH5, involving NOD-like receptors, TNF, and p53 pathways. These genes are potential diagnostic markers and therapeutic targets for as, providing an important basis for the development of targeted intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.